N

NGM Biopharmaceuticals Inc
F:0IK

Watchlist Manager
NGM Biopharmaceuticals Inc
F:0IK
Watchlist
Price: 1.41 EUR Market Closed
Market Cap: 117.7m EUR

Operating Margin
NGM Biopharmaceuticals Inc

6%
Current
7%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
6%
=
Operating Profit
15m
/
Revenue
251m

Operating Margin Across Competitors

No Stocks Found

NGM Biopharmaceuticals Inc
Glance View

Market Cap
117.7m EUR
Industry
Pharmaceuticals

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

0IK Intrinsic Value
5.03 EUR
Undervaluation 72%
Intrinsic Value
Price
N
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
6%
=
Operating Profit
15m
/
Revenue
251m
What is the Operating Margin of NGM Biopharmaceuticals Inc?

Based on NGM Biopharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 6%.

Back to Top